Clinical Trial Update: Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing [NA]

View source ↗

Summary

Clinical trial update examining the feasibility of CYP2C19 genetic testing to guide antiplatelet therapy in patients with stroke or transient ischemic attack.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Stroke
• Transient Ischemic Attack

Snippet

Sponsor: University of Alabama at Birmingham | Conditions: Stroke, Transient Ischemic Attack (TIA) | NA | Status: RECRUITING